What does the CDC think about GLP1 weight loss drugs?
The Centers for Disease Control and Prevention (CDC) is an American public health agency that monitors a huge variety of diseases and health issues facing Americans today. They were key participants during the 2020 COVID pandemic, and a source of information and policy that 330+ million Americans rely on.
The CDC is focused intensely on obesity, and helping Americans navigate it:
CDC
Knock on effects from obesity are varied but in particular type 2 diabetes affects more than 37 million people in the united states, with 96 million people being pre-diabetic.
This is one of the most serious public health problems our nation has ever faced, and it has enormous and far-reaching consequences.
The CDC has a Division of Diabetes Translation (DDT) that is dedicated to using science to turn the tide in Diabetes epidemic:
CDC
What is their stance on GLP1?
The CDC supports and affirms GLP1 as effective for weight loss, blood sugar management and more.
GLP1 is recognized as a diabetes medication, and has wide eligibility for Americans suffering from type 2 diabetes.
CDC
The CDC finds that:
- 8 in 10 adults with type 2 diabetes are eligible (so there is wide eligibility, which is key for widespread change) to use GLP1 drugs
- GLP1 drugs (and others) are effective
- GLP1 drugs (and others) are beneficial for blood sugar management and reduce risk for diabetes complications
The take home message is simple:
GLP-1s and SGLT-2s can be effective for people with type 2 diabetes. They help to lower blood sugar levels and help protect against related diabetes risk factors, notably heart disease and kidney disease.
You can go straight to their cited research and read it for yourself.
What isn't discussed?
Many CDC articles (and the linked study) does not go into the risks of GLP1 RA drugs like Ozempic, Wegovy, Mounjaro and others.
GLP1.guide has covered many risks to GLP1 drugs, so those are worth taking a look at, before starting a regimen or talking to your doctor.
